ACE and Nephropathy: Our group investigated the antiproteinuric effect of ACE inhibition (benazepril 10 mg/day or perindopril 4 mg/day) in relation to ACE I/D polymorphism in a short-term observational followup study in 83 NIDDM patients with overt nephropathy (urinary protein excretion over 500 mg/day) classified into three groups in accordance with ACE genotypes (17 DD; 33 ID; 33 II) and prospectively followed up for 3 months [34].